IL6 and Alzheimer disease: The administration of BEOV significantly reduced the levels of inflammatory factors, including tumor necrosis factor-a (TNFa), interleukin-6 (IL6), and interleukin-1b (IL1b), both in AD mice brains and in Aβ threatened BV2 microglia.